The Role of KRAS G12C Inhibitors in Frontline Metastatic NSCLC
December 7th 2023
Joshua K. Sabari, MD, and Edward B. Garon, MD, MS, discuss the role and potential impact of KRAS G12C inhibitors in the frontline setting, highlighting the potential of monotherapy and in combination with a PD-1/PD-L1 inhibitor.